beta

You're viewing our new website - find out more

Publication - Consultation Paper

Prostate cancer clinical quality performance indicators: engagement document

Published: 6 May 2016
ISBN:
9781786522542

Document explaining the process of, and inviting engagement on, revision of the prostate cancer QPIs.

37 page PDF

544.5kB

37 page PDF

544.5kB

Contents
Prostate cancer clinical quality performance indicators: engagement document
Footnotes

37 page PDF

544.5kB

Footnotes

a. TNM classification is a system for staging the extent of cancer. T describes the size of the tumour.
N refers to the involvement of the lymph nodes. M refers to the presence of metastatic disease.

b. Prostate Specific Antigen ( PSA) is a protein made by the prostate gland and found in the blood. Prostate cancer, and other benign conditions, can increase PSA levels in the blood.

c. Immediate therapy would be within 31 days of MDT meeting (pre treatment)

d. Docetaxel should be started within 90 days of first dose of hormone therapy.

e. Validated tools appropriate for this measurement would be:

  • The Expanded Prostate Cancer Index Composite ( EPIC) Urinary Assessment
  • Incontinence Questionnaire ( ICIQ)

Contact